Does HAART efficacy translate to effectiveness? Evidence for a trial effect

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Menezes, Prema ^a,b   Miller, William C ^a,b   Wohl, David A ^a   Adimora, Adaora A ^a,b   Leone, Peter A ^a,b   Eron, Joseph J ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b University of North Carolina at Chapel Hill   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; VIRUS INHIBITION; VIRUS REPLICATION; BLOOD; CLINICAL TRIAL (TOPIC); RISK FACTOR; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL TRIALS AS TOPIC; FEMALE; HIV INFECTIONS; HUMANS; MALE; RISK FACTORS; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 79960283934     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021824     Document Type: Article

References (46)

1. Braunholtz DA, Edwards SJ, Lilford RJ, (2001) Are randomized clinical trials good for us (in the short term)? Evidence for a "trial effect". J Clin Epidemiol 54: 217-224.
2. Lantos JD, (1999) The "inclusion benefit" in clinical trials. J Pediatr 134: 130-131.
3. Peppercorn JM, Weeks JC, Cook EF, Joffe S, (2004) Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet 363: 263-270.
4. Silverman WA, (2002) Disclosing the "inclusion benefit". J Perinatol 22: 261-262.
5. ECRI Evidence Report: Patients' reasons for participating in clinical trials and effect of trial participation on patient outcomes. (2002) Available at: https://www.ecri.org/Documents/Clinical_Trials_Patient_Guide_Evidence_Report.pdf. Accessed June 27, 2008.
6. Stiller CA, (1994) Centralised treatment, entry to trials and survival. Br J Cancer 70: 352-362.
7. Vist GE, Hagen KB, Devereaux PJ, Bryant D, Kristoffersen DT, Oxman AD, (2005) Systematic review to determine whether participation in a trial influences outcome. BMJ 330: 1175.
8. Napravnik S, Edwards D, Stewart P, Stalzer B, Matteson E, et al. (2005) HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia. J Acquir Immune Defic Syndr 40: 34-40.
9. Napravnik S, Eron JJ Jr, McKaig RG, Heine AD, Menezes P, Quinlivan E, (2006) Factors associated with fewer visits for HIV primary care at a tertiary care center in the Southeastern U.S. AIDS Care 18 (Suppl 1): S45-50.
10. Lampe FC, Gatell JM, Staszewski S, Johnson MA, Pradier C, et al. (2006) Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002. Arch Intern Med 166: 521-528.
11. Barros AJ, Hirakata VN, (2003) Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res Methodol 3: 21.
12. McNutt LA, Wu C, Xue X, Hafner JP, (2003) Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol 157: 940-943.
13. Zou G, (2004) A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 159: 702-706.
14. The European Agency for the Evaluation of Medicinal Products (2001) Evaluation of Medicines for Human Use. Committee for Proprietary Medicinal Products. Points to Consider on Missing Data. London, 15 November 2001.
15. Delucchi KL, (1994) Methods for the analysis of binary outcome results in the presence of missing data. J Consult Clin Psychol 62: 569-575.
16. Hollis S, (2002) A graphical sensitivity analysis for clinical trials with non-ignorable missing binary outcome. Stat Med 21: 3823-3834.
17. Kalayjian RC, Landay A, Pollard RB, Taub DD, Gross BH, et al. (2003) Age-related immune dysfunction in health and in human immunodeficiency virus (HIV) disease: association of age and HIV infection with naive CD8+ cell depletion, reduced expression of CD28 on CD8+ cells, and reduced thymic volumes. J Infect Dis 187: 1924-1933.
18. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, et al. (2008) Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 358: 2095-2106.
19. Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW, et al. (2003) Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 349: 2293-2303.
20. Shafer RW, Smeaton LM, Robbins GK, De Gruttola V, Snyder SW, et al. (2003) Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 349: 2304-2315.
21. Zolopa A AJ, Komarow L, Sanchez A, et al. (2008) Immediate vs Deferred ART in the Setting of Acute AIDS-related Opportunistic Infection: Final Results of a Randomized Strategy Trial, ACTG A5164.[Abstract 142]. 15th Conference on Retroviruses and Opportunistic Infections. Boston 2008.
22. Eron J Jr, Yeni P, Gathe J Jr, Estrada V, DeJesus E, et al. (2006) The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 368: 476-482.
23. Fischl MA, Ribaudo HJ, Collier AC, Erice A, Giuliano M, et al. (2003) A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. J Infect Dis 188: 625-634.
24. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, et al. (2006) Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 354: 251-260.
25. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, et al. (2004) Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. J Amer Med Assoc 292: 191-201.
26. Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, et al. (2004) Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 350: 1850-61.
27. Once-Daily PI/NNRTI Therapy Combinations for Treatment Naive, HIV Infected Patients in Resource-Limited Conditions. Available at:http://clinicaltrials.gov/ct2/show/NCT00084136?term=ACTG5175&rank=2.
28. Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults. Available at:http://clinicaltrials.gov/ct2/show/NCT00118898?term=actg5202&rank=2.
29. Mildvan DTC, Gross R, Andrade A, et al. (2007) Randomized Comparison in Treatment-naïve Patients of Once-daily vs Twice-daily Lopinavir/ritonavir-based ART and Comparison of Once-daily Self-administered vs Directly Observed Therapy. [Abstract 138] 14th Conference on Retroviruses and Opportunistic Infections; Los Angeles, 2007.
30. Murphy RL, Brun S, Hicks C, Eron JJ, Gulick R, et al. (2001) ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS 15: F1-9.
31. Moore RD, Keruly JC, Gebo KA, Lucas GM, (2005) An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002. J Acquir Immune Defic Syndr 39: 195-198.
32. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, et al. (1999) Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 341: 1865-1873.
33. Walmsley S, Bernstein B, King M, Arribas J, Beall G, et al. (2002) Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 346: 2039-2046.
34. Phillips AN, Grabar S, Tassie JM, Costagliola D, Lundgren JD, Egger M, (1999) Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups. AIDS 13: 2075-2082.
35. Sabin CA, Phillips AN, (2001) Treatment comparisons in HIV infection: the benefits and limitations of observational cohort studies. J Antimicrob Chemother 47: 371-375.
36. (1984) Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery. Comparability of entry characteristics and survival in randomized patients and nonrandomized patients meeting randomization criteria. J Am Coll Cardiol 3: 114-128.
37. King SB, Barnhart HX, Kosinski AS, Weintraub WS, Lembo NJ, et al. (1997) Angioplasty or surgery for multivessel coronary artery disease: comparison of eligible registry and randomized patients in the EAST trial and influence of treatment selection on outcomes. Emory Angioplasty versus Surgery Trial Investigators. Am J Cardiol 79: 1453-1459.
38. McKay JR, Alterman AI, McLellan AT, Boardman CR, Mulvaney FD, et al. (1998) Random versus nonrandom assignment in the evaluation of treatment for cocaine abusers. J Consult Clin Psychol 66: 697-701.
39. Strandberg TE, Salomaa VV, Vanhanen HT, Naukkarinen VA, Sarna SJ, et al. (1995) Mortality in participants and non-participants of a multifactorial prevention study of cardiovascular diseases: a 28 year follow up of the Helsinki Businessmen Study. Br Heart J 74: 449-54.
40. Williford WO, Krol WF, Buzby GP, (1993) Comparison of eligible randomized patients with two groups of ineligible patients: can the results of the VA Total Parenteral Nutrition clinical trial be generalized? J Clin Epidemiol 46: 1025-1034.
41. Flather M, Delahunty N, Collinson J, (2006) Generalizing results of randomized trials to clinical practice: reliability and cautions. Clin Trials 3: 508-512.
42. Elting LS, Cooksley C, Bekele BN, Frumovitz M, Avritscher EB, et al. (2006) Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants. Cancer 106: 2452-2458.
43. Corbie-Smith G, Thomas SB, Williams MV, Moody-Ayers S, (1999) Attitudes and beliefs of African Americans toward participation in medical research. J Gen Intern Med 14: 537-546.
44. Gifford AL, Cunningham WE, Heslin KC, Andersen RM, Nakazono T, et al. (2002) Participation in research and access to experimental treatments by HIV-infected patients. N Engl J Med 346: 1373-1382.
45. Cheung AM, Lee Y, Kapral M, Scher J, Ho I, et al. (2008) Barriers and motivations for women to participate in cardiovascular trials. J Obstet Gynaecol Can 30: 332-337.
46. Fayter D, McDaid C, Eastwood A, (2007) A systematic review highlights threats to validity in studies of barriers to cancer trial participation. J Clin Epidemiol 60: 990-1001.